Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study

Mimura, Wataru; Ishiguro, Chieko; Maeda, Megumi; Murata, Fumiko; Fukuda, Haruhisa

doi:10.1016/j.ijid.2022.10.001

Cited by 9 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous reports on the VENUS Study showed COVID-19 vaccine effectiveness against infection and symptomatic infection among the population aged <65 years during the waves of the Delta variant. 21 We did not consider the underlying diseases because the study used only the HER-SYS and VRS data. These data did not include sufficient information on the risk factors related to underlying diseases for severe COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…To the best of our knowledge, this study is the first to use HER-SYS, VRS, and claims data, although several studies have assessed the COVID-19 vaccine effectiveness in Japan. 13 – 15 , 21 , 31 , 32 …”

Section: Discussionmentioning

confidence: 99%

“… 20 We have previously reported the results of the VENUS Study, estimating the vaccine effectiveness of mRNA vaccines against infection (83.8%) and symptomatic infection (89.8%) at 7 days after the second dose in the population aged 16–64 years during the Delta-predominant period using COVID-19 case data linked with COVID-19 vaccination data. 21 However, there was no information on the severity of COVID-19 or comorbidities. Therefore, we used VENUS Study data linked with medical claims to adjust background factors and assess the effectiveness against COVID-19-related hospitalization, in addition to infection and symptomatic infection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

Mimura,

Ishiguro,

Terada-Hirashima

et al. 2024

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

Background We evaluated the effectiveness of the BNT162b2 vaccine against infection, symptomatic infection, and hospitalization in older people during the Delta-predominant period (July 1 to September 30, 2021). Methods We performed a population-based cohort study in an older adult population aged ≥65 years using data from the Vaccine Effectiveness, Networking, and Universal Safety Study conducted from January 1, 2019, to September 30, 2021, in Japan. We matched BNT162b2-vaccinated and -unvaccinated individuals in a 1:1 ratio on the date of vaccination of the vaccinated individual. We evaluated the effectiveness of the vaccine against infection, symptomatic infection, and coronavirus disease (COVID-19)-related hospitalization by comparing the vaccinated and unvaccinated groups. We estimated the risk ratio and risk difference using the Kaplan–Meier method with inverse probability weighting. The vaccine effectiveness was calculated as (1 − risk ratio) × 100%. Results The study included 203,574 matched pairs aged ≥65 years. At 7 days after the second dose, the vaccine effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization was 78.1% (95% confidence interval [CI], 65.2–87.8%), 79.1% (95% CI, 64.6–88.9%), and 93.5% (95% CI, 83.7–100%), respectively. Conclusion BNT162b2 was highly effective against infection, symptomatic infection, and hospitalization in Japan’s older adult population aged ≥65 years during the Delta-predominant period.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

Mimura,

Ishiguro,

Terada-Hirashima

et al. 2024

Journal of Epidemiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The VENUS Study database described in this study has already been used to generate evidence on the effectiveness of the COVID-19 vaccine [33] , [34] . The effectiveness of COVID-19 vaccination against infection can be analyzed using only the VRS (containing vaccination records) and the HER-SYS (containing information on COVID-19 cases), which allows for an investigation of all residents within the participating municipalities.…”

Section: Discussionmentioning

confidence: 99%

Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study

Fukuda¹,

Maeda²,

Murata³

2023

Vaccine

Self Cite

View full text Add to dashboard Cite

“…All patients underwent blood tests, and computed tomography (CT) scans on the first day of admission before initiation of COVID‐19 adjuvant therapy. The epidemic period for strains prior to the Omicron strain and the Omicron strain endemic period were defined as April 1, 2020 to December 31, 2021 and January 1, 2022 to March 31, 2023, respectively, according to the prevalence of the Omicron strain in Japan [12]. Subsequently, these patient groups were named the “Pre‐omicron group” and “Omicron group,” respectively.…”

Section: Methodsmentioning

confidence: 99%

Comparative outcomes of hemodialysis patients facing pre‐Omicron and Omicron COVID‐19 epidemics

Beppu,

Fukuda,

Otsubo

et al. 2023

Ther Apher Dial

View full text Add to dashboard Cite

IntroductionThis study elucidates factors affecting the severity and mortality in pre‐Omicron and Omicron strains of SARS‐CoV‐2 and vaccination impact.MethodsThis single‐center retrospective observational study included 1598 hospitalized COVID‐19 patients. Patients were grouped into “pre‐Omicron” and “Omicron” periods. The endpoint was severe COVID‐19 (oxygen saturation [SpO2] < 94%). Logistic regression examined associations between clinical factors, including hemodialysis (HD), and the endpoint.ResultsThe HD patient mortality rate dropped from 16% pre‐Omicron to 4% during the Omicron epidemic. HD was significantly associated with the study endpoint in both epidemics. Unvaccinated patients had a greater risk of reaching the study endpoint among patients receiving HD.ConclusionThese findings suggest that the Omicron variant, alongside vaccination and healthcare innovations, led to improved prognoses for HD patients with COVID‐19. However, HD patients remain at a greater risk for severe COVID‐19. Increased vaccination rates and optimized healthcare resources can improve this vulnerable population's prognoses.

show abstract

Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study

Cited by 9 publications

References 6 publications

Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study

Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study

Comparative outcomes of hemodialysis patients facing pre‐Omicron and Omicron COVID‐19 epidemics

Contact Info

Product

Resources

About